GenSight Biologics Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 33
Employees
  • Stock Symbol
  • SIGHT
Stock Symbol
  • Share Price
  • $9.06
  • (As of Friday Closing)

GenSight Biologics General Information

Description

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence and optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is in ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases that would otherwise lead to blindness.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Stock Exchange
PAR
Primary Office
  • 74 Rue du Faubourg Saint-Antoine
  • 75012 Paris
  • France
+33 01 00 00 00 00

GenSight Biologics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GenSight Biologics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.06 $9.02 $3.50 - $12.31 $414M 45.9M 178K -$0.85

GenSight Biologics Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 410,639 352,416 79,328 45,767
Revenue 11,043 5,009 784 0
EBITDA (29,367) (35,760) (32,992) (38,624)
Net Income (32,931) (38,774) (34,555) (39,477)
Total Assets 80,164 58,252 36,387 42,300
Total Debt 16,696 17,773 8,063 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GenSight Biologics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GenSight Biologics‘s full profile, request access.

Request a free trial

GenSight Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegene
Biotechnology
Paris, France
33 As of 2021
00000
000000000 00000

000000 0

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
00000000000 0000000
Ardsley, NY
000 As of 0000
00000
000000000 - 00000

00000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
0000000000000
New York, NY
0 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GenSight Biologics Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Acorda Therapeutics Formerly VC-backed Ardsley, NY 000 00000 000000000 - 00000
00000 Corporation New York, NY 0 00000 000000000 00000
0000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 00000 000000000
0000000 Venture Capital-Backed San Carlos, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 28 competitors. Get the full list »

GenSight Biologics Executive Team (10)

Name Title Board Seat Contact Info
Thomas Gidoin Chief Financial Officer
Marion Ghibaudo Ph.D Chief Technology Officer
Didier Pruneau Chief Scientific Officer
Magali Taiel MD Chief Medical Officer
Bernard Gilly Ph.D Co-Founder, Chief Executive Officer & Board Member
You’re viewing 5 of 10 executive team members. Get the full list »

GenSight Biologics Board Members (7)

Name Representing Role Since
Bernard Gilly Ph.D Self Co-Founder, Chief Executive Officer & Board Member 000 0000
Michael Wyzga Self Chairman 000 0000
You’re viewing 2 of 7 board members. Get the full list »

GenSight Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GenSight Biologics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GenSight Biologics‘s full profile, request access.

Request a free trial